AzurRx BioPharma, Inc. — FY2020 Form 10-K Summary
Filing identity: The request names Gridai Technologies Corp., but the supplied filing is for AzurRx BioPharma, Inc. (Nasdaq: AZRX). It reports the fiscal year ended December 31, 2020, not a separate fourth-quarter report. The filing was signed March 31, 2021.
Business context
AzurRx is a clinical-stage biopharmaceutical company developing locally acting gastrointestinal therapies. Its lead candidate, MS1819, is being studied for exocrine pancreatic insufficiency associated with cystic fibrosis (CF) and chronic pancreatitis. On December 31, 2020, the company licensed niclosamide formulations for COVID-19 gastrointestinal infections and immune-checkpoint-inhibitor-associated colitis (ICI-AC). It has no approved products and has generated no product revenue.
Financial performance and position
| Metric | FY2020 / December 31, 2020 | FY2019 / December 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, including acquired license | $19.1 million | $8.7 million |
| General and administrative expense | $7.3 million | $6.1 million |
| Total operating expenses | $26.4 million | $14.7 million |
| Net loss | $32.7 million | $15.2 million |
| Net loss per share | $1.15 | $0.68 |
| Cash used in operating activities | $11.2 million | $14.0 million |
| Cash and cash equivalents | $6.1 million | $0.2 million |
| Total assets | $12.9 million | $8.9 million |
| Total liabilities | $15.6 million | $4.3 million |
| Stockholders’ equity (deficit) | $(2.6) million | $4.6 million |
The 2020 R&D increase was principally due to a $13.25 million charge for the First Wave niclosamide license; cash R&D spending declined year over year amid reduced clinical activity, partly related to COVID-19. Interest expense rose to $5.84 million from $0.43 million, largely from amortization of debt discounts and accrued interest on convertible debt. No meaningful operating margin is applicable given zero revenue.
At year-end, current assets were $7.87 million against current liabilities of $15.55 million, implying negative working capital of about $7.68 million. The MD&A reports negative working capital of approximately $7.7 million, while a note to the financial statements states approximately $4.7 million; investors should reconcile this inconsistency. Year-end current liabilities included $13.25 million payable related to the First Wave license and a $552,000 insurance-premium note. No convertible debt remained outstanding at year-end. The Series B preferred stock carried a 9% cumulative dividend and an aggregate liquidation preference of approximately $21.4 million.
After year-end, the company reported approximately $18 million gross proceeds from January and March 2021 offerings and approximately $4.6 million gross proceeds from warrant exercises. The filing does not provide a clear post-financing cash balance or a definitive cash runway.
Changes, outlook, and material items
- Net loss more than doubled year over year, principally reflecting the niclosamide license charge and higher interest expense. Operating cash use improved, but the company remained dependent on external financing.
- The First Wave license requires a $9.0 million upfront cash payment, an additional $1.25 million due June 30, 2021, potential milestones of up to $37 million per indication, and mid-single-digit royalties on net sales. The upfront payment was made in January 2021.
- In March 2021, the company reported topline OPTION 2 results: MS1819 was described as safe and well tolerated, but the trial did not meet its primary efficacy endpoint; most patients did not reach the required fat-absorption level. Management attributed uneven performance to the enteric capsule and planned a microbead formulation and another Phase 2 study.
- The MS1819 Combination Trial enrolled 18 patients. Interim results in the first five patients met the primary endpoint, with CFA above 80% across visits and reported improvements in several secondary measures; full topline data were expected in Q2 2021.
- Management planned 2021 clinical programs for niclosamide: a Phase 2 COVID-19 GI trial and a Phase 1b/2a ICI-AC trial. These were plans, not demonstrated clinical outcomes.
- COVID-19 had delayed enrollment and could further affect trials, vendors, manufacturing, regulatory timelines, and access to capital. The company relies on third parties for manufacturing and clinical trials.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern emphasis: recurring losses, negative operating cash flows, and financing dependence raise substantial doubt about the company’s ability to continue as a going concern. Management’s financing plans do not remove that uncertainty.
- Financings and preferred-stock exchange rights create potential substantial dilution. The company also had a large outstanding warrant overhang. Stockholders approved an increase in authorized common shares to 250 million and authorized a possible 1-for-5 to 1-for-10 reverse split; the board had not effected the split as of the filing.
- The company reported no material pending legal proceedings. Management said disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the source is AzurRx BioPharma’s FY2020 10-K, despite the request metadata naming Gridai Technologies and “2020 Q4.”
- Reconcile the filing’s conflicting negative working-capital figures and assess the timing and settlement of the $13.25 million First Wave license payable.
- Verify cash remaining after the 2021 financings, license payments, warrant exercises, and operating expenditures; the filing provides no clear updated cash balance or runway.
- Review complete OPTION 2 and Combination Trial data, the rationale and cost for MS1819 reformulation, and the actual initiation and results of planned niclosamide trials.
- Assess dilution from preferred-stock exchange rights, warrants, options, and subsequent offerings, as well as the company’s ability to fund obligations and meet clinical milestones.